Metropolitan Life Insurance Company (MetLife)’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,129	Closed	-$98.9K	–	2481
2023 Q2	$98.9K	Buy	2,129 +114	+6%	+$3.94K	﹤0.01%	1022
2023 Q1	$57.7K	Sell	2,015 -208	-9%	-$6.16K	﹤0.01%	1312
2022 Q4	$69.4K	Buy	2,223 +375	+20%	+$12.2K	﹤0.01%	1276
2022 Q3	$37.5K	Hold	1,848	–	–	﹤0.01%	1652
2022 Q2	$28.7K	Buy	1,848 +711	+63%	+$12.2K	﹤0.01%	1847
2022 Q1	$21.8K	Sell	1,137 -3,377	-75%	-$60.3K	﹤0.01%	2050
2021 Q4	$114K	Buy	+4,514	New	+$132K	﹤0.01%	2399

Metropolitan Life Insurance Company (MetLife)'s DICE Position: Q3 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 2,129 shares — an estimated $98.9K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $114K in Q4 2021. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 2,129 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $98.9K.
Metropolitan Life Insurance Company (MetLife) first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
Metropolitan Life Insurance Company (MetLife)'s DICE Therapeutics, Inc. Common Stock position peaked at $114K in Q4 2021.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.